Concomitant EGFR and KRAS mutations in alk-rearranged lung cancer

Annals of Oncology

Volumn 26, Issue 5, 2015, Pages 1035-1036

  Rossi, G ^a   Baldi, L ^b   Barbieri, F ^a   Bertolini, F ^a   Tiseo, M ^c  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ANAPLASTIC LYMPHOMA KINASE GENE; CANCER SURVIVAL; DISEASE ACTIVITY; EGFR GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; LETTER; LUNG CANCER; LUNG CARCINOGENESIS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; ONCOGENE; ONCOGENE K RAS; PRIORITY JOURNAL; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SURVIVAL RATE; DNA MUTATIONAL ANALYSIS; FEMALE; GENETICS; LUNG TUMOR; MALE; PROCEDURES; PROTO ONCOGENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84929079737     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv067     Document Type: Letter

References (5)

1. Won JK, Keam B, Koh J et al. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Ann Oncol 2015; 26: 348-354.
2. Baldi L, Mengoli MC, Bisagni A et al. Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells. Lung Cancer 2014; 86: 291-295.
3. Cabillic F, Gros A, Dugay F et al. Parallel FISH and immunohistochemistry studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol 2014; 9: 295-306.
4. Yang JJ, Zhang XC, Su J et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res 2014; 20: 1383-1392.
5. Solomon BJ, Mok T, Kim DW et al. First-line crizotinib versus chemotherapy in ALKpositive lung cancer. N Engl J Med 2014; 371: 2167-2177.